[Featured Stock] FromBio Discovers Solution to Promote Hair Growth... Patents Hair Follicle-Based Technology for Hair Loss Treatment

[Asia Economy Reporter Hyungsoo Park] FromBio is showing strong performance. The news that it has registered a patent related to the cultivation method of dermal papilla cells that promote hair growth appears to be influencing its stock price.

As of 10:05 AM on the 5th, FromBio is trading at 8,170 KRW, up 22.67% from the previous day.

A FromBio representative explained, "Dermal papilla cells supply oxygen and nutrients to the cells that make up hair follicles, playing a role in hair growth and hair follicle cycle regulation. When the proliferation of dermal papilla cells is promoted, hair becomes healthier, hair growth is stimulated, and hair loss can be prevented."

They added, "In relation to the development of stem cell treatments for hair loss, we registered patents in April and August for adipose-derived stem cell cryopreservation agents and methods for isolating adipose-derived stem cells, respectively. With the newly registered patent, we have achieved the development of 'a serum-free medium composition for culturing dermal papilla cells and a method for culturing dermal papilla cells using the same.'"

When dermal papilla cells were cultured in a medium free of animal-derived serum, it was confirmed that cell proliferation and the expression levels of hair-related genes were similar or increased compared to the conventional dermal papilla cell culture medium containing animal serum. Serum-supplemented media refer to synthetic culture media containing various nutrients with added serum, artificially prepared to allow the proliferation of primary cells from humans, monkeys, mice, and others. Previous studies mainly used culture media supplemented with nutrient-rich fetal bovine serum (FBS) to promote cell growth. FromBio explained that the process of obtaining fetal bovine serum posed environmental, ethical, and cost challenges, and there were disadvantages such as the risk of contamination by external viruses and unstable supply.

Hong In-gi, Director of the Bio Research Institute at FromBio, stated, "We are conducting multifaceted research and analysis to develop a safe and effective stem cell treatment for hair loss," and added, "This achievement is one of the foundational technologies used in hair follicle production necessary for hair loss treatment and itself holds high commercial potential in the culture medium market."